P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
Kulasekararaj, A., Füreder, W., McDonald, A., Malherbe, J. L. R., Gandhi, S., Collins, D., Cornpropst, M., Dobo, S., Farmer, M. K., Kargl, D., Sheridan, W., Griffin, M., Risitano, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS
McDonald, A., Malherbe, J. L. R., Kulasekararaj, A., Füreder, W., Griffin, M., Cornpropst, M., Farmer, M. K., Kargl, D., Collins, D., Sheridan, W., Risitano, A.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article